US data Johnson’s Vaccine Launches Very Well But the 6-month short-term landscape plummeted to 10%, while Sputnik in the older group was only half and half.
Dr. Anan Chongkaewwatana, virologist Director of Animal Health and Management Innovation Research Group National Center for Genetic Engineering and Biotechnology (Biotech), National Science and Technology Development Agency (NSTDA) posted via Facebook on October 15, 64, stating that “one dose vaccine of Johnson&Johnson (Janssen) made a very good debut. With the efficacy of vaccines similar to other types of 2-injection vaccines But data collected in the United States where the vaccine is being used is large. Compared to the mRNA vaccine that uses 2 injections, it’s clear that J&J’s immunizations are inadequate for long-term protection against COVID-19. The vaccine’s efficacy at the beginning was about 85% and dropped sharply to 10% within 6 months. The performance degradation was significantly different.
The only vaccine designed similar to J&J, Russia’s Sputnik Light, recently published research. Delta protection can be as high as 88.61% in the 18-29 year old population, but its effectiveness is reduced to around 50-55% in the elderly. Taking the J&J graph into account, the Sputnik Light’s expectations don’t seem exhilarating. That the research team tried to communicate at all … a single-dose covid vaccine. Not likely to go
source
https://www.medrxiv.org/con…/10.1101/2021.10.13.21264966v1
https://www.medrxiv.org/con…/10.1101/2021.10.08.21264715v1″
.jpg?fit=300%2C300&ssl=1)
